

RESEARCH

Open Access

The effects of phosphanegold(I) thiolates on the biological properties of *Acanthamoeba castellanii* belonging to the T4 genotype

Ruqaiyyah Siddiqui¹, Farhat Abjani¹, Chien Ing Yeo², Edward R. T. Tiekink² and Naveed Ahmed Khan^{1*}

Abstract

Background: Gold compounds have shown promise in the treatment of non-communicable diseases such as rheumatoid arthritis and cancer, and are considered of value as anti-microbial agents against Gram-negative and Gram-positive bacteria, and have anti-parasitic properties against *Schistosoma mansoni*, *Trypanosoma brucei*, *Plasmodium falciparum*, *Leishmania infantinum*, *Giardia lamblia*, and *Entamoeba histolytica*. They are known to affect enzymatic activities that are required for the cellular respiration processes.

Methods: Anti-amoebic effects of phosphanegold(I) thiolates were tested against of clinical isolate of *A. castellanii* belonging to the T4 genotype by employing viability assays, growth inhibition assays, encystation assays, excystation assays, and zymographic assays.

Results: The treatment of *A. castellanii* with the phosphanegold(I) thiolates tested (i) had no effect on the viability of *A. castellanii* as determined by Trypan blue exclusion test, (ii) did not affect amoebae growth using PYG growth medium, (iii) did not inhibit cellular differentiation, and (iv) had no effect on the extracellular proteolytic activities of *A. castellanii*.

Conclusion: Being free-living amoeba, *A. castellanii* is a versatile respirator and possesses respiratory mechanisms that adapt to various aerobic and anaerobic environments to avoid toxic threats and adverse conditions. For the first time, our findings showed that *A. castellanii* exhibits resistance to the toxic effects of gold compounds and could prove to be an attractive model to study mechanisms of metal resistance in eukaryotic cells.

Keywords: *Acanthamoeba*, Gold compounds, Cytotoxicity assays, Zymography, Encystation, Excystation

Background

Acanthamoeba is a free living pathogenic protist that can cause cutaneous lesions, a vision-threatening keratitis, and a rare but fatal infection of the brain, identified as granulomatous amoebic encephalitis [1–4]. *Acanthamoeba* keratitis infection is of explicit concern given the rise in the number of wearers of contact lens worldwide, a population susceptible to this infection. Treatment involves hourly topical application of a mixture of drugs comprising polyhexamethylene biguanide or chlorhexidine digluconate together with propamidine isethionate or hexamidine. Moreover, chloramphenicol or

neomycin is also given to prevent mixed bacterial infection [5]. Treatment lasts for several months [5, 6]. Furthermore, the treatment is problematic and cumbersome, in part due to the ability of this facultative parasite to go through phenotypic interchanging into a double-walled cyst form, which is impervious to many anti-microbial drugs and harsh conditions, and an active vegetative trophozoite stage that is more vulnerable to anti-microbials, often leading to recurrence of infection [7–9]. Consequently, there is a crucial need to develop anti-microbials targeting both the cyst stage and the trophozoite stage of *Acanthamoeba*.

Gold compounds have been well recognised for their putative properties and potential medical applications [10, 11]. For example, the assessment of the potential anti-cancer activity and the determination of signalling

* Correspondence: naveed5438@gmail.com

¹Department of Biological Sciences, Faculty of Science and Technology, Sunway University, 47500 Bandar Sunway, Selangor, Malaysia

Full list of author information is available at the end of the article



54 pathways for apoptosis of phosphane gold(I) carboni-
 55 midthioates, $\text{Ph}_3\text{PAu}[\text{SC}(\text{OR})=\text{NPh}]$, R = Me, Et and
 56 iPr, and related species have been carried out recently
 F1 57 [12–14], see Fig. 1 for chemical structures. Moreover,
 58 closely related compounds have shown potential as
 59 anti-microbial agents against Gram-positive bacteria
 60 [15]. Gold(I) compounds have potential medical appli-
 61 cations and shown to possess anti-tumour activities
 62 [16, 17], anti-parasitic [18] and anti-microbial activi-
 63 ties [19–21] via a variety of mechanisms including
 64 respiration. In this study, for the first time, we deter-
 65 mined the effects of phosphane-gold(I) thiolates,
 66 AAu1–AAu3, Fig. 1, on a keratitis-causing isolate of
 67 *A. castellanii* belonging to the T4 genotype. Further-
 68 more, the effects on viability, growth, encystation and
 69 excystation are examined.

70 Methods

71 Chemicals

72 All chemicals were purchased from Sigma Labs (Poole,
 73 Dorset, England), unless otherwise stated. The phosphane-
 74 gold(I) thiolates, AAu1–AAu3, were prepared and
 75 characterised using methodology as previously described
 76 [14]. The molecular structures and weights of AAu1–
 77 AAu3 are given in Fig. 1. A stock solution (10 mM)
 78 chloroform was prepared and stored at -20°C until
 79 used. Control cultures contained the same volume of re-
 80 spective solvents.

81 Cultures of *A. castellanii*

82 *A. castellanii* belonging to the T4 genotype (ATCC
 83 50492) is a clinical isolate that was initially isolated from
 84 a keratitis patient and grown in 75 cm^2 tissue culture
 85 flasks in 10 mL at a cell density of 1×10^5 cells per mL in
 86 PYG medium [proteose peptone 0.75% (w/v), yeast


extract 0.75% (w/v) and glucose 1.5% (w/v)] without
 shaking at 30°C as described previously [22, 23]. At this
 cell density, parasites reach confluency within 48 h. Ac-
 tive trophozoites are attached to the bottom of the flasks
 while any dormant cells are non-adherent in the super-
 natant. To obtain trophozoites, supernatant was aspi-
 rated and 10 mL of RPMI-1640 was added. Next, flasks
 were placed on ice for 20 min to detach bound amoebae
 followed by gentle tapping and observed under the
 inverted microscope to ensure amoebae detachment had
 occurred. Finally, the parasites were collected in 50 mL
 tubes, followed by centrifugation at $1500 \times g$ for 5 min,
 resuspended in one mL of RPMI-1640 and used in
 experiments.

Amoebicidal assays

To determine amoebicidal activity of AAu1–AAu3, *A.*
castellanii trophozoites (5×10^5 amoebae/0.5 mL/well)
 were incubated in RPMI-1640 with various concentra-
 tions of AAu1–AAu3 in 24-well plates as described pre-
 viously [20–24]. Plates were incubated at 37°C for 24 h.
 Following this incubation, amoebae viability was deter-
 mined by adding 0.1% Trypan blue and numbers of live
 (non-stained) and dead (stained) *A. castellanii* were enu-
 merated using a haemocytometer. The counts from *A.*
castellanii incubated with RPMI-1640 alone, and the
 solvent alone (chloroform) were used as controls. Data
 are represented as the mean \pm standard error of at least
 three independent experiments. To determine whether
 the effects of AAu1–AAu3 are irreversible, *A. castellanii*,
 5×10^5 trophozoites, were incubated with AAu1–AAu3
 for 24 h as described above. After this incubation, amoebae
 were centrifuged for 10 min at $1,000 \times g$ and super-
 natant were aspirated, followed by the addition of
 0.5 mL of RPMI-1640. This process was repeated 3X to
 remove extracellular AAu1–AAu3. Finally, *A. castellanii*
 were re-suspended in PYG as a food source and inocu-
 lated in 24-well plates. Plates were incubated at 37°C
 for up to 72 h and re-emergence of trophozoites was
 considered as viable amoebae, and absence of trophozoites
 was considered as non-viable amoebae. In some exper-
 iments, plates were incubated for up to a week to
 observe the emergence of viable trophozoites.

Amoebistatic assays

To determine the effect of AAu1–AAu3 on the growth
 of *A. castellanii*, assays were performed by exposing $5 \times$
 10^5 trophozoites to different concentrations of AAu1–
 AAu3 in growth medium, i.e., PYG in 24-well plates.
 Next, the plates were incubated at 30°C for 48 h. For
 controls, 5×10^5 trophozoites were inoculated in 100%
 PYG medium, 100% non-nutritive PBS and respective
 amounts of solvents plus PYG medium and incubated in
 the above-mentioned conditions. After this incubation,



139 the number of amoebae was determined by haemocyt-
140 omer counting. All experiments were performed at
141 least three times in duplicate.

142 Preparation of *A. castellanii* cysts and excystation assays

143 To prepare *A. castellanii* cysts, encystation was induced
144 by inoculating 5×10^6 *A. castellanii* trophozoites onto
145 non-nutrient agar plates [prepared using 3% (w/v) bac-
146 teriological agar) and incubating at 30 °C for up to
147 14 days [25]. Food deprivation resulted in trophozoite
148 transformation into the cyst form. Next, 10 mL of PBS
149 was added to each plate. Cysts were then gently scraped
150 off the agar surface using a cell scraper. PBS containing
151 cysts was collected in 15 mL tube and centrifuged at
152 $3000 \times g$ for 10 min to pellet cysts. The supernatant was
153 aspirated and cysts resuspended in RPMI-1640, enumer-
154 ated using a haemocytometer and used in experiments.
155 To determine the effects of AAu1–AAu3 on excystation,
156 assays were performed by inoculating *A. castellanii* cysts
157 (5×10^4 cysts per mL PYG per well of 24-well plates) in
158 the presence or absence of different concentrations of
159 AAu1–AAu3. Plates were incubated at 30 °C and ob-
160 served every 24 h under the inverted microscope for the
161 emergence of viable trophozoites for up to 72 h.

162 Encystation assays

163 Encystation assays were performed as described previ-
164 ously [25]. Briefly, 2×10^6 amoebae were incubated in
165 0.5 mL of PBS containing 50 mM $MgCl_2$ and 10% glu-
166 cose (i.e., encystation trigger) per well of 24-well plates.
167 The plates were incubated at 30 °C for 72 h without
168 shaking. After this incubation, amoebae viability was
169 quantified using a haemocytometer via Trypan blue ex-
170 clusion assay. Next, SDS (0.5% final conc.) was added for
171 10 min. At this concentration, SDS solubilizes amoebae
172 trophozoites but not cysts. Finally cysts were enumerated
173 using a haemocytometer and used in experiments. To de-
174 termine the effects of AAu1–AAu3 on encystation, assays
175 were performed in the presence of different concentra-
176 tions of drugs. Briefly 2×10^6 amoebae were incubated in
177 PBS with various concentrations of drugs and incubated
178 at room temperature for 20 min. Following this, 50 mM
179 $MgCl_2$ and 10% glucose was added as a trigger for encyst-
180 ation and plates were incubated at 30 °C for 72 h. Finally,
181 parasites counts were determined using a haemocytom-
182 eter. Amoebae incubated without inhibitors and encyst-
183 ation trigger were used as controls. The respective
184 amounts of solvents were used as solvent controls.

185 Zymographic assays

186 The extracellular proteolytic activities of *Acanthamoeba*
187 were determined using zymographic assays as previously
188 described [26]. Briefly, *A. castellanii* were incubated in the
189 presence or absence of various concentrations of AAu1–

AAu3 for 24 h. Next day, cell-free supernatants (CM, con-
190 ditioned medium) were collected by centrifugation. The
191 CM were electrophoresed on sodium dodecyl sulfate-
192 polyacrylamide gel electrophoresis (SDS-PAGE) containing
193 gelatin (2 mg/mL) as a protease substrate as previously de-
194 scribed [26]. Following electrophoresis, gels were washed
195 in 2.5% Triton X-100 (w/v) for 60 min, then incubated in
196 developing buffer (50 mM Tris–HCl, pH 7.5, containing
197 10 mM $CaCl_2$) at 37 °C overnight. Next day, gels were
198 stained with Coomassie Brilliant Blue. Areas of gelatin di-
199 gestion were visualised as non-staining regions in the gel. 200

201 Statistical analysis

202 Statistical significance for differences was evaluated
203 using 2 sample *t*-test; two-tailed distribution, comparing
204 the mean of two independent groups in Excel. A critical
205 value of $P < 0.05$ was used for all analysis. For graphical
206 representation of the data, y-axis error bars indicate the
207 standard error of the data for each point on the figure.


208 Results

209 Phosphanegold(II) thiolates, AAu1–AAu3, did not affect *A.* 210 *castellanii* trophozoites viability

211 To ascertain the effects of AAu1–AAu3, amoebicidal as-
212 says were performed as stated in Materials and Methods.
213 The results revealed that AAu1–AAu3 did not exhibit
214 anti-amoebic effects against *A. castellanii* trophozoites
215 (Fig. 2a and b). In the presence of 100, 200 and 300 μM F2
216 AAu1, the number of viable amoebae was $3.41 \times 10^5 \pm$
217 1.12×10^4 , $2.84 \times 10^5 \pm 5.51 \times 10^3$ and $2.62 \times 10^5 \pm 3.47 \times$
218 10^4 , respectively. However, this was not significant when
219 compared to the respective solvent controls (5, 10 and
220 15 μL chloroform). Likewise, for 100, 200 and 300 μM
221 AAu2, the number of viable amoebae was $2.88 \times 10^5 \pm$
222 1.75×10^4 , $2.72 \times 10^5 \pm 4.73 \times 10^4$ and $2.30 \times 10^5 \pm 2.14 \times$
223 10^4 , respectively. For 100, 200 and 300 μM AAu3, the
224 number of viable amoebae was $2.94 \times 10^5 \pm 1.56 \times 10^4$,
225 $2.76 \times 10^5 \pm 3.09 \times 10^4$ and $2.23 \times 10^5 \pm 3.39 \times 10^4$, re-
226 spectively (Fig. 2a). Overall, the results showed no effects
227 of AAu1–AAu3 on amoebae viability.

228 Phosphanegold(II) thiolates, AAu1–AAu3, did not exhibit 229 amoebistatic effects against *A. castellanii* trophozoites

230 Amoebistatic assays were performed in the presence or
231 absence of AAu1–AAu3. When incubated in 100% growth
232 medium, the number of amoebae increased from 5×10^5
233 to $8.78 \times 10^5 \pm 3.21 \times 10^4$ (Fig. 3). In contrast, amoebae in- F3
234 cubated in non-nutritive RPMI medium had no growth
235 stimulatory effect but exhibited reduced number of amoe-
236 bae i.e., the amoebae count decreased from 5×10^5 to
237 $3.29 \times 10^5 \pm 6.63 \times 10^4$ (Fig. 3). For AAu1–AAu3, the re-
238 sults revealed that there were no amoebistatic effects
239 against *A. castellanii* even at 300 μM concentrations. For
240 AAu1–AAu3, the number of amoebae increased from $5 \times$




f2.1
f2.2
f2.3
f2.4
f2.5
f2.6
f2.7
f2.8

241 10^5 to $9.56 \times 10^5 \pm 8.42 \times 10^4$, $7.02 \times 10^5 \pm 9.38 \times 10^4$ and
242 $9.85 \times 10^5 \pm 3.07 \times 10^4$, respectively at 300 μ M.

243 Phosphanegold(I) thiolates, AAu1-AAu3, did not affect
244 excystation in *A. castellanii*

245 When incubated in growth medium, the number of
246 amoebae increased from 5×10^4 to $3.91 \times 10^5 \pm 1.63 \times$

10^4 as compared to 5×10^4 to $1.24 \times 10^5 \pm 1.38 \times 10^4$ in
247 RPMI medium, which is a non-nutritive medium
248 (Fig. 4a). However, for AAu1-AAu3, the number of
249 F4 amoebae increased from 5×10^4 to $3.50 \times 10^5 \pm 1.63 \times$
250 10^4 , $3.73 \times 10^5 \pm 2.50 \times 10^4$ and $3.21 \times 10^5 \pm 2.81 \times 10^4$,
251 respectively at 300 μ M (Fig. 4a). Nonetheless, this was
252 not significant when compared to the respective growth
253



f3.1
f3.2
f3.3
f3.4

254 medium control and the results revealed that none of
255 the compounds tested had any effects on excystation,
256 and amoebae were able to excyst at rates comparable to
257 controls (Fig. 4b).

258 **Phosphanegold(I) thiolates, AAu1-AAu3, did not affect**
259 **encystation in *A. castellanii***

260 To determine the effects of AAu1-AAu3 on *A. castella-*
261 *nii* encystation, assays were performed in the presence
262 and absence of these compounds. When incubated in
263 encystation medium, the number of amoebae decreased
F5 264 from 5×10^5 to $1.73 \times 10^5 \pm 2.50 \times 10^3$ (Fig. 5). However,
265 for AAu1-AAu3, the number of amoebae was reduced
266 from 5×10^5 to $1.18 \times 10^5 \pm 4.75 \times 10^4$, $1.17 \times 10^5 \pm$
267 2.06×10^4 and $1.17 \times 10^5 \pm 1.44 \times 10^4$, respectively, at
268 300 µM (Fig. 5). However, this was not significant when
269 compared to the respective encystation medium control.
270 The results revealed that none of the trial compounds
271 tested had any effects on encystation.


272 **Phosphanegold(I) thiolates, AAu1-AAu3, did not effect *A.***
273 ***castellanii* extracellular proteolytic activity**

274 To determine the effect of AAu1-AAu3 on the extracel-
275 lular proteases of *A. castellanii*, zymographic assays were
276 performed using gelatin as substrate as described in ma-
277 terials and methods. In the absence of any trial com-
278 pound, *A. castellanii* exhibited proteolytic activities and

a visible band of 140 kDa was observed (Fig. 6). Simi- 279 F6
280 larly, both, *A. castellanii* treated in the presence of dif-
281 ferent concentrations of AAu1-AAu3 and in RPMI
282 alone exhibited extracellular proteases similar levels
283 (Fig. 6).

284 **Discussion**


285 Gold(I) complexes have potential medical applications
286 [10, 11]. Thus, gold(I) derivatives have been explored for
287 anti-tumour activity [16, 17] as well as anti-parasitic [18]
288 and anti-microbial agents [19-21]. Gold has properties
289 such as high thermal/chemical stability and resistant to
290 oxidation, yet is mechanically soft with high electric con-
291 ductivity enabling its applications in several disciplines
292 ranging from healthcare to engineering. For example,
293 gold compounds have been successfully used in the
294 treatment of rheumatoid arthritis and are shown to slow
295 down the progression of rheumatic disorder [27, 28].
296 Many of the biologically active gold(I) compounds con-
297 tain thiolates and/or phosphines as ligands [10, 11, 16,
298 17, 21] and inhibit thioredoxin reductase [29, 30]. More
299 recently, it is shown that the gold(I) compounds exhibit
300 anti-parasitic activities such as targeting *Schistosoma*
301 *mansoni* [31], *Trypanosoma brucei* [32], *Echinococcus*
302 *granulosus* [33], *Plasmodium falciparum* [34], *Leish-*
303 *mania infantinum* [35] *Giardia lamblia* [36], and *Ent-*
304 *amoeba histolytica* [37]. Furthermore, it was shown that



f4.1
 f4.2
 f4.3
 f4.4
 f4.5
 f4.6

305 gold(I) compounds target *E. histolytica* by inhibiting
 306 thioredoxin reductase activity [37]. The anti-bacterial ac-
 307 tivities of gold(I) compounds showed that these com-
 308 pounds affect *Clostridium difficile* and *Treponema*
 309 *denticola* by disrupting the selenium metabolism by tar-
 310 geting selenoproteins required for energy [38, 39], while
 311 *Staphylococcus aureus* growth is inhibited by gold(I)
 312 compounds [40]. Other studies proposed targets includ-
 313 ing the inhibition of mitochondrial enzymes and of the
 314 proteasome compounds [41, 42] and the inhibition of
 315 the zinc finger protein poly (adenosine diphosphate
 316 (ADP) ribose) polymerase 1 (PARP-1) [43, 44]. Notably,


317 PARP's are crucial proteins that are important in drug
 318 resistance in cancer as they play an essential role in
 319 DNA repair by detecting DNA strand breaks and cata-
 320 lyzing poly (ADP-ribosylation) [45]. Other biological tar-
 321 gets of gold(I) compounds with prokaryotic and
 322 eukaryotic cells are yet to be discovered.
 323 Based on these findings, it was logical to test the anti-
 324 amoebic effects of phosphane gold(I) thiolates, AAu1–
 325 AAu3, on the biological properties of *A. castellanii* be-
 326 longing to the T4 genotype. The results revealed that
 327 AAu1–AAu3 did not show any effects on the biological
 328 properties of the parasite. This was determined by



f5.1
f5.2
f5.3

329 performing (i) viability assays using Trypan blue exclu-
330 sion test, (ii) amoebae growth using PYG growth
331 medium, (iii) cellular differentiation using encystation
332 and excystation assays and (iv) enzymatic activities by
333 determining extracellular proteases profiles. The re-
334 ported results are highly reproducible and consistently
335 showed that AAu1–AAu3 do not affect the biological
336 properties of *A. castellanii*. There could be several

337 explanations for the findings observed in this study. For
338 example, the mode of action of gold requires it to enter
339 the cell, via the hydrophobic cell membrane, to produce
340 damage, most likely through transmembrane proteins
341 that may be different in *A. castellanii*. Notably, gold(I)
342 compounds are well known to affect enzymatic activities
343 that are required for the cellular respiration processes.
344 Being one of the most ubiquitous protists, the natural



f6.1
f6.2
f6.3
f6.4

345 habitat of *Acanthamoeba* is the environment with di-
 346 verse respiratory mechanisms and wide exposure to
 347 metals, thus *Acanthamoeba* is likely to possess mecha-
 348 nisms to inhibit the toxic effects exerted by metals. *A.*
 349 *castellanii* is well known as a versatile respirator and
 350 possesses several mitochondria per cell and respiratory
 351 mechanisms that adapt to various aerobic and anaerobic
 352 environments to dodge toxic threat and adverse condi-
 353 tions. It is possible that the toxic effects of metals are
 354 compensated by switching the type of respiration or the
 355 use of an efflux system to rid toxic metals. Future stud-
 356 ies are needed to test higher concentration of phosphane-
 357 gold(I) thiolates compounds and/or in combining
 358 phosphane gold(I) thiolates with current anti-amoeba
 359 drugs, such as chlorhexidine to determine their im-
 360 proved efficacy against pathogenic *Acanthamoeba*. Over-
 361 all, these findings suggest that *Acanthamoeba* exhibits
 362 resistance to toxic effects of gold(I) compounds and
 363 could prove to be an attractive model to study mecha-
 364 nisms of metal resistance in eukaryotic cells.

365 Conclusions

366 Although gold compounds have shown promise in the
 367 treatment of non-communicable diseases such as
 368 rheumatoid arthritis, anti-tumour activities, antibacterial
 369 properties, and anti-parasitic properties against proto-
 370 zoan pathogens, *T. brucei*, *P. falciparum*, *L. infantinum*,
 371 *G. lamblia*, and *E. histolytica*, often by targeting respir-
 372 ation pathways, our studies demonstrated that *A. castel-*
 373 *lanii* exhibited resistance against their toxic effects. The
 374 gold derivatives tested had no effect on the viability of
 375 *A. castellanii*, did not inhibit amoebae growth, or cellu-
 376 lar differentiation processes or extracellular proteolytic
 377 activities. As *Acanthamoeba* is a versatile respirator, it
 378 can adapt to various aerobic and anaerobic environ-
 379 ments to avoid toxic threats. Our studies suggest that
 380 *Acanthamoeba* could prove to be a useful model to
 381 study mechanisms of metal resistance in eukaryotic cells.

382 Acknowledgements

383 Not applicable.

384 Funding

385 This work was supported by the University Research Grant Scheme No. 2015-
 386 03, Sunway University, Malaysia.

387 Availability of data and materials

388 For data requests, please contact Distinguished Professor Naveed Ahmed
 389 Khan (Naveed5438@gmail.com).

390 Authors' contributions

391 RS conceived the study. CIY and ET synthesised and characterised AAu1-
 392 AAu3. FA and NAK carried out all biological experiments. FA and RS
 393 collected relevant literature and wrote the first draft. NAK corrected the
 394 original manuscript. All authors approved the final manuscript.

395 Competing interests

396 The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Not applicable.

Author details

¹Department of Biological Sciences, Faculty of Science and Technology,
 Sunway University, 47500 Bandar Sunway, Selangor, Malaysia. ²Research
 Centre for Crystalline Materials, Sunway University, 47500 Bandar Sunway,
 Selangor, Malaysia.

Received: 17 November 2016 Accepted: 9 February 2017

References

- Khan NA. Pathogenesis of *Acanthamoeba* infections. *Microb Pathogen*. 2003; 34:277–85.
- Khan NA. *Acanthamoeba*: biology and increasing importance in human health. *FEMS Microbiol Rev*. 2006;30:564–95.
- Visvesvara GS, Moura H, Schuster FL. Pathogenic and opportunistic free-living amoebae: *Acanthamoeba* spp., *Balamuthia mandrillaris*, *Naegleria fowleri*, and *Sappinia diploidea*. *FEMS Immunol. Med. Microbiol*. 2007;50:1–26.
- Marciano-Cabral F, Cabral G. *Acanthamoeba* spp. as agents of disease in humans. *Clin Microbiol Rev*. 2003;16:273–307.
- Perez-Santonia JJ, Kilvington S, Hughes R, Tufail A, Metheson M, Dart JKG. Persistently culture positive *Acanthamoeba* keratitis: in vivo resistance and in vitro sensitivity. *Ophthalmology*. 2003;110:1593–600.
- Ejcker L, Seal D, Warhurst D, Wright P. *Acanthamoeba* keratitis: resistance to medical therapy. *Eye*. 1990;4:835–8.
- Aksozek A, McClellan K, Howard K, Niederhorn JY, Alizadeh H. Resistance of *Acanthamoeba castellanii* cysts to physical, chemical, and radiological conditions. *J Parasitol*. 2002;88(3):621–3.
- Lloyd D, Turner NA, Khunkitti W, Hann AC, Furr JR, Russell AD. Encystation in *Acanthamoeba castellanii*: development of biocide resistance. *J Eukaryot Microbiol*. 2001;48(1):11–6.
- Turner NA, Russel AD, Furr JR, Lloyd D. Emergence of resistance to biocides during differentiation of *Acanthamoeba castellanii*. *J Antimicrob Chem*. 2000; 46:27–34.
- Ott I. On the medicinal chemistry of gold complexes as anticancer drugs. *Coord Chem Rev*. 2009;253:1670–81.
- Berners-Price SJ, Filipovska A. Gold compounds as therapeutic agents for human diseases. *Metallomics*. 2011;3:863–73.
- Yeo CI, Ooi KK, Akim AM, Ang KP, Fairuz ZA, Halim SNBA, Ng SW, Seng H-L, Tiekink ERT. The influence of R substituents in triphenylphosphinegold(I) carbonimidothioates, Ph₃PAu[SC(OR) = NPh] (R = Me, Et and iPr), upon in vitro cytotoxicity against the HT-29 colon cancer cell line and upon apoptotic pathways. *J Inorg Biochem*. 2013;127:24–38.
- Ooi KK, Yeo CI, Ang K-P, Akim AM, Cheah Y-K, Halim SNA, Seng H-L, Tiekink ERT. Phosphane gold(I) thiolates, Ph₃PAu[SC(OR) = NC₂H₅Me-4] for R = Me, Et and iPr, induce apoptosis, cell cycle arrest and inhibit cell invasion of HT-29 colon cancer cells through modulation of the nuclear factor-κB activation pathway and ubiquitination. *J Biol Inorg Chem*. 2015;20:855–73.
- Ooi KK, Yeo CI, Mahandaran T, Ang KP, Akim AM, Cheah Y-K, Seng H-L, Tiekink ERT. G₂/M cell cycle arrest on HT-29 cancer cells and toxicity assessment of triphenylphosphane gold(I) carbonimidothioates, Ph₃PAu[SC(OR) = NPh], R = Me, Et, and iPr, during zebrafish development. *J Inorg Biochem*. 2017. doi:10.1016/j.jinorgbio.2016.11.008.
- Yeo CI, Sim JH, Khoo CH, Goh ZJ, Ang KP, Cheah YK, Fairuz ZA, Halim SN, Ng SW, Seng HL, Tiekink ER. Pathogenic Gram-positive bacteria are highly sensitive to triphenylphosphane gold (O-alkylthiocarbamates), Ph₃PAu[SC(OR) = N(p-tolyl)] (R = Me, Et and iPr). *Gold Bull*. 2013;46:145–52.
- Tiekink ERT. Gold derivatives for the treatment of cancer. *Crit Rev Hematol Oncol*. 2002;42:225–45.
- Zou T, Lum CT, Lok C-N, Zhang J-J, Che C-M. Chemical biology of anticancer gold(III) and gold(I) complexes. *Chem Soc Rev*. 2015;44:8786–801.
- Navarro M. Gold complexes as potential anti-parasitic agents. *Coord Chem Rev*. 2009;253:1619–26.
- Fillat MF, Gimeno MC, Laguna A, Latorre E, Ortego L, Villacampa MD. Synthesis, structure and bactericidal activity of (Aminophosphane) gold(I) Thiolate complexes. *Eur J Inorg Chem*. 2011;9:1487–95.

Q2

- 464 20. Ray S, Mohan R, Singh JK, Samantaray MK, Shaikh MM, Panda D, Ghosh P. Anticancer and antimicrobial metallopharmaceutical agents based on
465 palladium, gold, and silver N-heterocyclic carbene complexes. *J Am Chem*
466 *Soc.* 2007;129:15042–53.
- 468 21. Glišić BD, Djuran MI. Gold complexes as antimicrobial agents: an overview
469 of different biological activities in relation to the oxidation state of the gold
470 ion and the ligand structure. *Dalton Trans.* 2014;43:5950–69.
- 471 22. Sissons J, Alsam S, Stins M, Ortega-Rivas A, Lorenzo-Morales J, Faull J, Khan
472 NA. Use of In vitro assays to determine effects of human serum in
473 biological characteristics of *Acanthamoeba Castellanii*. *J Clin Microbiol.* 2006;
474 44:2595–600.
- 475 23. Sissons J, Kim KS, Stins M, Jayasekera S, Alsam S, Khan NA. *Acanthamoeba*
476 *castellani* induces host cell death via a phosphatidylinositol 3-kinase-
477 dependent mechanism. *Infect Immun.* 2005;73:2704–8.
- 478 24. Siddiqui R, Jarroll EL, Khan NA. *Balamuthia mandrillaris*: role of galactose in
479 encystment and identification of potential inhibitory targets. *Exp Parasitol.*
480 2010;126:22–7.
- 481 25. Dudley R, Jarroll EL, Khan NA. Carbohydrate analysis of *Acanthamoeba*
482 *castellani*. *Exp Parasitol.* 2009;122:338–43.
- 483 26. Matin A, Stins M, Kim KS, Khan NA. *Balamuthia mandrillaris* exhibits
484 metalloprotease activities. *FEMS Immunol Med Microbiol.* 2006;47:83–91.
- 485 27. Shaw III CF. Gold-based therapeutic agents. *Chem Rev.* 1999;99:2589–600.
- 486 28. Kean WF, Kean IRL. Clinical pharmacology of gold. *Inflammopharmacology.*
487 2008;16:112–25.
- 488 29. Bindoli A, Rigobello MP, Scutari G, Gabbiani C, Casini A, Messori L.
489 Thioredoxin reductase: a target for gold compounds acting as potential
490 anticancer drugs. *Coord Chem Rev.* 2009;253:1692–707.
- 491 30. Eisler R. Chrysotherapy: a synoptic review. *Inflammation Res.* 2003;52:
492 487–501.
- 493 31. Kuntz AN, Davioud-Charvet E, Sayed AA, Califf LL, Dessolin J, Amer ESJ,
494 Williams DL. Thioredoxin glutathione reductase from *Schistosoma mansoni*:
495 an essential parasite enzyme and a key drug target. *PLoS Med.* 2007;4, e206.
- 496 32. Lobanov AV, Gromer S, Salinas G, Gladyshev VN. Selenium metabolism in
497 *Trypanosoma*: characterization of selenoproteomes and identification of a
498 Kinetoplastida-specific selenoprotein. *Nucleic Acids Res.* 2006;34:4012–24.
- 499 33. Bonilla M, Denicola A, Novoselov SV, Turanov AA, Protasio D, Izmendi D,
500 Gladyshev VN, Salinas G. Platyhelminth mitochondrial and cytosolic redox
501 homeostasis is controlled by a single thioredoxin glutathione reductase and
502 dependent on selenium and glutathione. *J Biol Chem.* 2008;283:17896–907.
- 503 34. Sannella AR, Casini A, Gabbiani C, Messori L, Billa AR, Vincieri FF, Majori G,
504 Severini C. New uses for old drugs. Auranofin, a clinically established
505 antiarthritic metallo drug, exhibits potent antimalarial effects in vitro:
506 mechanistic and pharmacological implications. *FEBS Lett.* 2008;582:844–7.
- 507 35. Ilari A, Baiocco P, Messori L, Fiorillo A, Boffi A, Gramiccia M, Di Muccio T,
508 Colotti G. A gold-containing drug against parasitic polyamine metabolism:
509 the X-ray structure of trypanothione reductase from *Leishmania infantum* in
510 complex with auranofin reveals a dual mechanism of enzyme inhibition.
511 *Amino Acids.* 2012;42:803–11.
- 512 36. Tejman-Yarden N, Miyamoto Y, Leitsch D, Santini J, Debnath A, Gut J,
513 McKerrow JH, Reed SL, Eckman L. A reprofiled drug, auranofin, is effective
514 against metronidazole-resistant *Giardia lamblia*. *Antimicrob Agents*
515 *Chemother.* 2013;57:2029–35.
- 516 37. Debnath A, Parsonage D, Andrade RM, He C, Cobo ER, Hirata K, Chen S,
517 Garcia-Rivera G, Orozco E, Martinez MB, Gunatilleke SS, Barrios AM, Arkin MR,
518 Poole LB, McKerrow JH, Reed SL. A high-throughput drug screen for
519 *Entamoeba histolytica* identifies a new lead and target. *Nature Med.* 2012;
520 18:956–62.
- 521 38. Jackson-Rosario J, Cowart D, Myers A, Tarrien R, Levine RL, Scott RA, Self WT.
522 Auranofin disrupts selenium metabolism in *Clostridium difficile* by forming
523 a stable Au-Se adduct. *J Biol Inorg Chem.* 2009;14:507–19.
- 524 39. Jackson-Rosario S, Self WT. Inhibition of selenium metabolism in the oral
525 pathogen *Treponema denticola*. *J Bacteriol.* 2009;191:4035–40.
- 526 40. Novelli F, Recine M, Sparatore F, Juliano C. Gold(I) complexes as
527 antimicrobial agents. *Farmaco.* 1999;54:232–6.
- 528 41. Berners-Price SJ, Filipovska A. Gold compounds as therapeutic agents for
529 human diseases. *Metallomics.* 2011;3:863–73.
- 530 42. Dalla Via L, Nardon C, Fregona D. Targeting the ubiquitin – proteasome
531 pathway with inorganic compounds to fight cancer: a challenge for the
532 future. *Future Med Chem.* 2012;4:525–43.
- 533 43. Serratrice M, Edate F, Mendes F, Scopelliti R, Zakeeruddin SM, Gratzel M,
534 Santos I, Cinellu MA, Casini A. Cytotoxic gold compounds: synthesis,
biological characterization and investigation on their inhibition properties of
the zinc finger protein PARP-1. *Dalton Trans.* 2012;41:3287–93.
44. Mendes F, Groessl M, Nazarov AA, Tsybin YO, Sava G, Santos I, Dyson PJ,
Casini A. Metal-based inhibition of poly(ADPribose)polymerase the guardian
angel of DNA. *J Med Chem.* 2011;54:2196–206.
45. Schreiber V, Dantzer F, Ame JC, De Murcia G. Poly(ADPribose): novel
functions for an old molecule. *Nat Rev Mol Cell Biol.* 2006;7:517–28.

Submit your next manuscript to BioMed Central
and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit



543
544